A practical look at pre-mixed sermorelin/ipamorelin blends — the GHRH plus GHRP rationale and the tracking tradeoffs of using one syringe.
At a glance
Pre-mixed sermorelin/ipamorelin vials are popular because they combine the two classes of GH secretagogue — a GHRH analog and a GHRP — in a single injection. The mechanism is sound; the convenience is real. The tradeoff is that you cannot tune one compound without changing the other, which is worth thinking about before you commit to a blend rather than two separate vials.
Sermorelin activates the GHRH receptor on pituitary somatotrophs. Ipamorelin activates the ghrelin/GHS receptor on the same cells. Together they produce a larger GH pulse than either alone, and ipamorelin has the advantage of relative selectivity — minimal cortisol or prolactin rise compared to older GHRPs like GHRP-6. The combined pulse is closer to a physiological surge than either compound alone produces.
Blends are typically dosed subcutaneously once or twice a day, with at least one dose at night and away from food. The ratio of sermorelin to ipamorelin is set by the compounder — common ratios exist but vary. Cycling on and off is standard. Because the half-lives are similar (both short), timing logic is the same as for the individual peptides.
A well-running blend produces noticeable sleep improvement and modest IGF-1 changes within a few months. Body composition shifts are slow and depend more on training and food than on the peptide. The pre-mix vial is convenient, but the cost is a loss of dose independence — you cannot push ipamorelin while holding sermorelin steady, or vice versa, without switching to separate vials.
In Peptide IA, log injection volume rather than peptide mass — the blend makes the per-compound math messy. Add sleep, glucose, recovery, and a weekly waist measurement. Note the compounder and lot if you switch vials, because ratio differences between compounders are real. Quarterly: IGF-1 attached to the log.
Sermorelin/ipamorelin blends are prescription compounded products. Quality control varies between pharmacies. Same contraindications apply as with any GH secretagogue: active malignancy, uncontrolled diabetes, pregnancy. The GH axis is not a casual lever to pull — clinician oversight is the appropriate baseline.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.